159191-56-7

Basic information

• Product Name: 4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID
• Synonyms: 4-(T-BUTYL DIMETHYLSILOXY) PHENYL BORONIC ACID;4-(TERT-BUTYL DIMETHYLSILOXY)PHENYL BORONIC ACID;4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID;4-(TERT-BUTYLDIMETHYLSILYOXY)PHENYLBORONIC ACID;AKOS BRN-0412;4-(TERT-BUTYLDIMETHYLSILYOXY)PHENYLBORON;4-(tert-Butyldimethylsilyloxy)benzeneboronic acid;4-(tert-ButyldiMethylsilyloxy)phenylboronic Acid (contains varying aMounts of Anhydride)
• CAS NO: 159191-56-7
• Molecular Formula: C₁₂H₂₁BO₃Si
• Molecular Weight: 252.19
• Product Categories: blocks;BoronicAcids;Aryl;Organoborons;Boronic acid;Boronic Acids;Boronic Acids and Derivatives;Boronic Acids;Aryl Boronic Acids;Boronic Acids and Derivatives;Chemical Synthesis;Monosubstituted Aryl Boronic Acids;Organometallic Reagents
• Mol File: 159191-56-7.mol

Chemical Properties

• Melting Point: 194-198 °C(lit.)
• Boiling Point: 321.358 °C at 760 mmHg
• Flash Point: 148.152 °C
• Appearance: /
• Density: 1.019g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.49
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 8.68±0.16(Predicted)
• CAS DataBase Reference: 4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID(159191-56-7)
• EPA Substance Registry System: 4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID(159191-56-7)

Safety Data

• Hazard Codes: Xi
• WGK Germany: 3
• Hazardous Substances Data: 159191-56-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is used as a reactant in asymmetric addition reactions with β-substituted cyclic enones, hydroarylation and heterocyclization with phenylpropiolates, and double Suzuki-Miyaura coupling reactions. It serves as a key intermediate in the synthesis of complex organic molecules due to its ability to participate in various types of chemical transformations.
Used in Material Science:
4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is used as a starting material for the synthesis of red electroluminescent polyfluorenes. These materials have potential applications in the development of organic light-emitting diodes (OLEDs) and other optoelectronic devices.
Used in Pharmaceutical Chemistry:
4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is used as a reactant in the synthesis of biologically active molecules, including phenylpyridone derivatives as MCH1R antagonists, atromentin and its O-alkylated derivatives, and gelatinases and MT1-MMP inhibitors. These molecules have potential therapeutic applications in various medical conditions, such as cancer, neurological disorders, and inflammatory diseases.
Used in the Pharmaceutical Industry:
4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is used as a synthetic building block for the development of novel drug candidates, particularly in the areas of oncology, neurology, and inflammation. Its unique reactivity and structural features make it a valuable asset in the design and synthesis of new therapeutic agents.
Used in the Material Science Industry:
4-(TERT-BUTYLDIMETHYLSILYLOXY)PHENYLBORONIC ACID is used as a precursor in the development of advanced materials for optoelectronics, such as red electroluminescent polyfluorenes. These materials have potential applications in the creation of more efficient and environmentally friendly OLEDs and other light-emitting technologies.

InChI:InChI=1/C12H21BO3Si/c1-12(2,3)17(4,5)16-11-8-6-10(7-9-11)13(14)15/h6-9,14-15H,1-5H3

Upstream product

• 106-41-2 4-bromo-phenol 
• 71597-85-8 (p-hydroxyphenyl)boronic acid 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 121-43-7 Trimethyl borate 
• 67963-68-2 t-butyldimethylsilyl-4-bromophenol 
• 5419-55-6 Triisopropyl borate 

Downstream Products

• 549503-31-3 N-hexyl-5-(p-tert-butyldimethylsilyloxyphenyl)-2-amino-1,4-pyrazine 

Relevant articles and documents

Flexible Analogues of Azaindole DYRK1A Inhibitors Elicit Cytotoxicity in Glioblastoma Cells

DYRK1A is a novel target for epidermal growth factor receptor (EGFR)-dependent glioblastoma and it represents a promising strategy for cancer therapy. DYRK1A inhibition has been found to promote EGFR degradation in glioblastoma cells by triggering endocyt

Structure-Activity Relationship and Mode-Of-Action Studies Highlight 1-(4-Biphenylylmethyl)-1H-imidazole-Derived Small Molecules as Potent CYP121 Inhibitors

CYP121 of Mycobacterium tuberculosis (Mtb) is an essential target for the development of novel potent drugs against tuberculosis (TB). Besides known antifungal azoles, further compounds of the azole class were recently identified as CYP121 inhibitors with

Polymerizable compounds. Liquid crystal composition and liquid crystal display device

A polymerizable compound having a formula of formula (I): Ring A, ring B, Z1 , Z2 , R, P, n And m are as described in the specification and the application patent range, respectively. The liquid crystal composition containing the pol

CHEMILUMINESCENT IMIDAZOPYRAZINONE-BASED PHOTOSENSITIZERS WITH AVAILABLE SINGLET AND TRIPLET EXCITED STATES

The present application describes the development of novel photosensitizers that can undergo self-excitation due to a chemiluminescent reaction, to produce readily-available singlet and/or triplet states and are composed by an imidazopyrazinone core. This core is functionalized with a variety of chromophores and spin converters, allowing to modulate the optical and photosensitizing properties. In one application, the chemiluminescent reaction is triggered by the superoxide anion, overexpressed in tumors, and by molecular oxygen, in aprotic solvents. The photosensitizers can be used in photodynamic therapy of cancer, without the need for external light sources and when triggered by a tumor marker, superoxide anion, while eliminating the restrictions of this therapy associated with tumor size and localization. The emission of light during the self-excitation reaction, and the resulting non-autofluorescence and low background noise, allow their use in tumor diagnostics. The photosensitizers can also be used without light sources and metal elements in photocatalysis reactions.

Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A

Dual-specificity tyrosine phosphorylation-related kinase 1A (DYRK1A) is a dual-specificity protein kinase that catalyses phosphorylation and autophosphorylation. Higher DYRK1A expression correlates with cancer, in particular glioblastoma present within the brain. We report here the synthesis and biological evaluation of new heterocyclic diphenolic derivatives designed as novel DYRK1A inhibitors. The generation of these heterocycles such as benzimidazole, imidazole, naphthyridine, pyrazole-pyridines, bipyridine, and triazolopyrazines was made based on the structural modification of the lead DANDY and tested for their ability to inhibit DYRK1A. None of these derivatives showed significant DYRK1A inhibition but provide valuable knowledge around the importance of the 7-azaindole moiety. These data will be of use for developing further structure-activity relationship studies to improve the selective inhibition of DYRK1A.

COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES

Coelenterazine analogs with different luminescence properties from conventional ones and coelenteramide analogs with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogs modified at the

Synthesis of macrocyclic ketones exploiting palladium-catalyzed activation of carboxylic acids as an enabling step

The novel synthesis of macrocyclic arylketones via palladium-catalyzed cross-coupling of arylboronic acids and carboxylic acids, activated by the treatment with di(N-succinimidyl) carbonate, is disclosed. This allows the high yielding synthesis of various

Design of a highly selective and potent class of non-planar estrogen receptorβ agonists

Selective activation of the estrogen receptorβ (ERβ) could be a safe approach to hormone replacement therapy for both women and men, in contrast to the estrogens currently used for women which activate both ERβ and ERα, occasionally causing severe side effects. The selective ERβ agonist AC-131 has shown efficacy in animal models of Parkinson's disease and neuropathic pain. With the use of AC-131 as template, herein we report the discovery, synthesis, and structure-activity relationship (SAR) study of a new class of dihydrobenzofurans as potent and selective ERβ agonists. The SAR was established by enantioselective synthesis, molecular modeling, and whole-cell-based functional assays. The most potent diastereomer, cis-10-SR, was shown to have an EC50 value of A T-shaped trans-SS diastereomer of 4-{3-fluoro-8-oxatricyclo[7.5.0.02,7]tetradeca-2,4,6-trien-1-yl}phenol (10) was found to be 1000-fold selective for ERβ over ERα.

COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES

Coelenterazine analogues with different luminescence properties from conventional ones and coelenteramide analogues with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogues modified at the 8-position of coelenterazine and coelenteramide analogues modified at the 2- or 3-position of coelenteramide.

SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES

The present invention provides a compound represented by Formula (II): wherein R1 is a chlorine atom, a fluorine atom, a methyl group or an ethynyl group; Ar is a group represented by the following Formula (a), Formula (b), Formula (c) or Formula (d): wherein R2 is a C1-6 alkyl group which may be substituted with one or more halogen atoms, a C1-6 alkoxy group which may be substituted with one or more halogen atoms, a C1-3 alkylthio group, a halogen atom, a C1-3 alkylcarbonyl group or a C2-5 alkynyl group which may be substituted with —OR4; R3 is a hydrogen atom or a C1-3 alkyl group; R4 is a hydrogen atom or a C1-3 alkyl group; provided that Ar is a group represented by Formula (a) when R1 is a fluorine atom, methyl group or an ethynyl group, and that R2 is methoxy group, an ethoxy group, an isopropyl group, a propyl group, a trifluoromethyl group, a trifluoromethoxy group, 2-fluoroethyl group or 1-propynyl group when R1 is a methyl group or a pharmaceutically acceptable salt or a solvate thereof and a pharmaceutical agent, a pharmaceutical composition and so on comprising the compound.